Inhibitory effects of levetiracetam on the high-voltage-activated L-type Ca2+ channels in hippocampal CA3 neurons of spontaneously epileptic rat (SER)

Brain Research Bulletin

Volumn 90, Issue 1, 2013, Pages 142-148

  Yan, Hai Dun ^a   Ishihara, Kumatoshi ^b,d   Seki, Takahiro ^a   Hanaya, Ryosuke ^b,e   Kurisu, Kaoru ^b   Arita, Kazunori ^b,e   Serikawa, Tadao ^c   Sasa, Masashi ^a,f  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f Nagisa Clinic   (Japan)

Author keywords

Ca2+ current; Hippocampal CA3 neuron; Levetiracetam (LEV); Patch clamp; Spontaneously epileptic rat (SER)

Indexed keywords

CALCIUM CHANNEL L TYPE; ETIRACETAM; NIFEDIPINE;

AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DEPOLARIZATION; EPILEPSY; FEMALE; HIPPOCAMPAL CA3 REGION; INHIBITION KINETICS; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; BIOPHYSICS; CALCIUM; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; EPILEPSY; FEMALE; HIPPOCAMPUS; MALE; MEMBRANE POTENTIALS; NEURAL INHIBITION; NEURONS; NIFEDIPINE; PATCH-CLAMP TECHNIQUES; PIRACETAM; RATS; RATS, MUTANT STRAINS; RATS, WISTAR;

EID: 84870509072     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.10.006     Document Type: Article

References (32)

1. Amano H., Amano T., Matsubayashi H., Ishihara K., Serikawa T., Sasa M. Enhanced calcium influx in hippocampal CA3 neurons of spontaneously epileptic rats. Epilepsia 2001, 42:345-350.
2. 2+ influx with mossy fiber stimulation in hippocampal CA3 neurons of spontaneously epileptic rats. Brain Research 2001, 910:199-203.
3. Birnstiel S., Wülfert E., Beck S.G. Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn-Schmiedeberg's Archives of Pharmcology 1997, 356:611-618.
4. Cai J.-Q., Ishihara K., Nagayama T., Serikawa T., Sasa M. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiractam from conventional antiepileptic drugs. Epilepsia 2005, 26:1362-1370.
5. Gower A.J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research 1995, 22:207-213.
6. Gower A.J., Noyer M., Verloes R., Gobert J., Wülfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. European Journal of Pharmacology 1992, 222:193-203.
7. Hanaya R., Sasa M., Ujihara H., Ishihara K., Serikawa T., Iida K., Akimitsu T., Arita K., Kurisu K. Suppression by topiramate of epleptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Research 1998, 789:274-282.
8. Hanaya R., Kiura Y., Serikawa T., Kurisu K., Arita K., Sasa M. Modulation of abnormal synaptic transmission ifn hippocampal CA3 neurons of spontaneously epilepitic rats (SERs) by levetiracetam. Brain Research Bulletin 2011, 86:334-339.
9. Ishihara K., Sasa M., Momiyama T., Ujihara H., Nakamura J., Serikawa T., Yamada J., Takaori S. Abnormal excitability of hippocampal CA3 pyramidal neurons of spontaneously epileptic rats (SER), a double mutant. Experimental Neurology 1993, 119:287-290.
10. Klein P., Herr D., Pearl P.L., Natale J., Levine Z., Nogay C., Sandoval F., Trzcinski S., Atabaki S.M., Tsuchida T., van der Anker J., Soldin S.J., He J., McCarter R. Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. Archives of Neurology 2012, 9(July):E1-E6.
11. Klitgaad H., Matagne A., Gobert J., Wulfer E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology 1998, 353:191-206.
12. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 1993, 232:147-158.
13. Löscher W., Honack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics 1998, 284:474-479.
14. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
15. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9861-9866.
16. Margineanu D.G., Klitgaard H. Inhibition of neuronal hyper-synchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacological Research 2000, 42:281-285.
17. Momiyama T., Ishihara K., Serikawa T., Moritake K., Sasa M. Effect of nicardipine on abnormal excitability of CA3 pyramidal cells in hippocampal slices of spontaneously epileptic rats. European Journal of Pharmacology 1995, 280:119-123.
18. 2+ current in pyramidal neurons of rat hippocampal slices. Neuroscience Letters 2001, 306:5-8.
19. Noyer M., Gillard M., Matagne A., Henichart J.-P., Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European Journal of Pharmacology 1995, 286:137-146.
20. Ohno Y., Ishihara S., Terada R., Serikawa T., Sasa M. Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model. Epilepsy Research 2010, 80:360-364.
21. Paxinos A., Watson C. The rat brain, in stereotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
22. Pellock J.M., Carman W.J., Thyagarajan V., Daniels T., Morris D.L., D'Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012, 79:1482-1489.
23. Sasa M., Ohno Y., Ujihara H., Fujita Y., Yoshimura M., Takaori S., Serikawa T., Yamada J. Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. Epilepsia 1988, 29:505-513.
24. Serikawa T., Kogishi K., Yamada J., Ohno Y., Ujihara H., Fujita Y., Sasa M., Takaori S. Long-term effects of continual intake of phenobarbital on the spontaneously epileptic rat. Epilepsia 1990, 31:9-14.
25. Serikawa T., Yamada J. Epileptic seizures in rats homozygous for two mutations, zitter and tremor. The Journal of Heredity 1986, 77:441-444.
26. Stefani A., Spadoni F., Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy?. Epilepsia 1997, 38:959-965.
27. Sugata S., Hanaya R., Kumafuji K., Tokudome M., Serikawa T., Kurisu K., Arita K., Sasa M. Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneopusly epileptic rats. Brain Research Bulletin 2011, 86:36-41.
28. Tokuda S., Sofue N., Ohno Y., Sasa M., Serikawa T. Inhibitory effects of levetiracetam on absence seizures in a novel absence-like epilepsy model, Groggy rat. Brain Research 2010, 1359:298-303.
29. Yan H.-D., Cai J.-Q., Ishihara K., Nagayama T., Serikawa T., Sasa M. Separation of antiepieltptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 2005, 46:1170-1177.
30. Yan H.-D., Ishihara K., Hanaya R., Kurisu K., Serikawa T., Sasa M. Voltage-dependent calcium channel abnormalities in hippocampal CA3 neurons of spontaneously epileptic rats. Epilepsia 2007, 48:758-764.
31. Yang X.F., Weisenfeld A., Rothman S.M. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007, 48:1861-1869.
32. 2+ currents. Seizure 2001, 10:279-286.